ReviewMaedica2026
Gastric Juice microRNAs in Gastric Cancer: What is the Evidence?
Review in Maedica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: So far, combining gastroscopy with biopsy remains the gold-standard for screening gastric cancer. Recently, the study of circulating microRNAs (miRNAs or miRs) has yielded valuable insights into gastric cancer prognosis. However, because these molecules are common to multiple cancer types, their clinical applicability remains uncertain. Materials and methods: We investigated the pertinent literature dealing with gastric juice microRNAs in gastric cancer patients. Only five original articles have investigated the feasibility of using gastric juice miRNAs as potential biomarkers to assist in screening for gastric cancer. Results: Gastric juice microRNAs proved correlated with high reliability, high sensitivity, high specificity and relative stability. Conclusion: MicroRNAs found in gastric juice may offer a promising alternative approach for gastric cancer screening without the need for biopsy. More studies are needed to reach safe conclusions. However, it seems that this novel potential biomarkers' testing is reliable and reproducible.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.